How much funding has Abcuro raised?

Abcuro has raised $407.3M in total funding, most recently a Series C round.

Who are Abcuro's investors?

Abcuro's investors include Sanofi Ventures, Bain Capital Life Sciences, Redmile Group, NEA, Mass General Brigham Ventures, Partners Innovation Fund.

Where is Abcuro headquartered?

Abcuro is headquartered in Newton, Massachusetts, United States.

What industry is Abcuro in?

Abcuro operates in Biotech, Healthcare.

Abcuro

Breakthrough Therapies for Autoimmune Diseases and Cancer

Newton, United States · Founded 2015 · $407.3M raised

Biotech

Healthcare

Headquarters: Newton, Massachusetts
Employees: 51–200
Founded: 2015
Business Model: B2B

Website: abcuro.com
Total Funding: $407.3M
Last Round: $200.0M Series CFeb 2025
Rounds: 5

About

Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies targeting KLRG1 (Killer cell Lectin-like Receptor G1) for rare autoimmune diseases and cancers. Its lead candidate ulviprubart (ABC008) is in Phase 2/3 pivotal trials for Inclusion Body Myositis (IBM) and Phase 1 trials for T-Cell Large Granular Lymphocytic Leukemia (T-LGLL). The company has raised over $200M in Series C financing led by New Enterprise Associates with participation from Sanofi Ventures, RA Capital, and Bain Capital Life Sciences.

Summary

Abcuro is a Biotech company based in Newton, United States, founded in 2015. It has raised $407.3M in total across 5 rounds, most recently a $200.0M Series C round in Feb 2025. Investors include Sanofi Ventures, Bain Capital Life Sciences and Redmile Group.